At the time of writing, 4D Molecular Therapeutics Inc [FDMT] stock is trading at $8.83, up 10.10%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The FDMT shares have gain 8.74% over the last week, with a monthly amount glided 4.50%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
4D Molecular Therapeutics Inc [NASDAQ: FDMT] stock has seen the most recent analyst activity on September 23, 2024, when Cantor Fitzgerald downgraded its rating to a Neutral. Previously, Barclays started tracking the stock with Overweight rating on April 15, 2024, and set its price target to $459. On April 15, 2024, Barclays initiated with a Overweight rating and assigned a price target of $45 on the stock. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $25 as its price target on October 26, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on October 24, 2023, and assigned it a price target of $32. In a note dated October 18, 2023, Leerink Partners upgraded an Outperform rating on this stock but restated the target price of $24.
For the past year, the stock price of 4D Molecular Therapeutics Inc fluctuated between $7.32 and $36.25. Currently, Wall Street analysts expect the stock to reach $41 within the next 12 months. 4D Molecular Therapeutics Inc [NASDAQ: FDMT] shares were valued at $8.83 at the most recent close of the market. An investor can expect a potential return of 364.33% based on the average FDMT price forecast.
Analyzing the FDMT fundamentals
According to 4D Molecular Therapeutics Inc [NASDAQ:FDMT], the company’s sales were 21.99M for trailing twelve months, which represents an -98.74% plunge. Gross Profit Margin for this corporation currently stands at -531.43% with Operating Profit Margin at -12026.86%, Pretax Profit Margin comes in at -10248.57%, and Net Profit Margin reading is -10248.57%. To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.28 and Total Capital is -0.29. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 8.14 points at the first support level, and at 7.45 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.33, and for the 2nd resistance point, it is at 9.83.
Ratios To Look Out For
It is important to note that 4D Molecular Therapeutics Inc [NASDAQ:FDMT] has a current ratio of 17.33. As well, the Quick Ratio is 17.33, while the Cash Ratio is 6.36. Considering the valuation of this stock, the price to sales ratio is 20.44, the price to book ratio is 0.83.
Transactions by insiders
Recent insider trading involved Bizily Scott, Chief Legal Officer, that happened on Sep 16 ’24 when 500.0 shares were sold. Chief Legal Officer, Bizily Scott completed a deal on Aug 19 ’24 to sell 500.0 shares. Meanwhile, Chief Legal Officer Bizily Scott sold 1750.0 shares on Jul 16 ’24.
